INDIANAPOLIS, IND. (August 22, 2023) – The Indiana Biosciences Research Institute (IBRI), a leading translational research organization, is pleased to announce an integrated drug discovery collaboration with BiomEdit, the most advanced microbiome company in animal health.
“This collaboration leverages the IBRI’s strong translational science capabilities in partnership with BiomEdit to pursue opportunities that otherwise would not happen,” said Alan Palkowitz, PhD, president and CEO of the IBRI. “Our Diabetes Center, combined with the power of our iPSC (induced pluripotent stem cell) Lab, will allow us to contribute to BiomEdit’s efforts to address unmet needs in animal health with the potential to impact human health.”
“The talented team at the IBRI brings unique capabilities, skills and innovative insights that will further our combined efforts to advance novel microbiome-based approaches to addressing chronic conditions in companion animals,” said Aaron Schacht, CEO of BiomEdit. “We’re also very interested in demonstrating how studying and developing products for animal health can create powerful translational insights as starting points for analogous human conditions.”
This collaboration utilizes the synergistic application of the IBRI’s drug discovery capabilities combined with the deep expertise of BiomEdit’s R&D team, which has advanced a novel approach to addressing a chronic condition with an engineered live bacterial therapeutic, looking to develop a new approach to keep cats healthy in a safe and sustainable way.
The collaboration between the IBRI and BiomEdit is underwritten by the Indiana 21st Century Research and Technology Fund (21 Fund), created by the Indiana Economic Development Corporation (IEDC).
“Access to the 21 Fund and Indiana’s full ecosystem of support for growth-stage companies like BiomEdit unlocks our ability to innovate transformative, novel solutions faster,” said Schacht.
